Non-bacterial thrombotic endocarditis in
Non-small-cell lung carcinoma
ROS1 protein, human
case report
endocarditis
Journal
Translational lung cancer research
ISSN: 2218-6751
Titre abrégé: Transl Lung Cancer Res
Pays: China
ID NLM: 101646875
Informations de publication
Date de publication:
31 Jan 2024
31 Jan 2024
Historique:
received:
31
07
2023
accepted:
15
11
2023
medline:
26
2
2024
pubmed:
26
2
2024
entrez:
26
2
2024
Statut:
ppublish
Résumé
Lung cancer is one of the tumor types with highest incidence of thromboembolic events (TE), especially adenocarcinoma subtype. Here we present two cases of NBTE in patients with NBTE is an infrequent disease which can cause severe neurological symptoms that impair quality of life, performance status and survival. Early clinical suspicion in patients with higher risk of TEs such as patients with rearrangements of
Sections du résumé
Background
UNASSIGNED
Lung cancer is one of the tumor types with highest incidence of thromboembolic events (TE), especially adenocarcinoma subtype.
Case Description
UNASSIGNED
Here we present two cases of NBTE in patients with
Conclusions
UNASSIGNED
NBTE is an infrequent disease which can cause severe neurological symptoms that impair quality of life, performance status and survival. Early clinical suspicion in patients with higher risk of TEs such as patients with rearrangements of
Identifiants
pubmed: 38404995
doi: 10.21037/tlcr-23-412
pii: tlcr-13-01-179
pmc: PMC10891407
doi:
Types de publication
Case Reports
Langues
eng
Pagination
179-185Informations de copyright
2024 Translational Lung Cancer Research. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-412/coif). J.R.B. reports travel support from Adamed and LEO Pharma, outside the submitted work. P.R. reports travel support from AstraZeneca, MSD, BMS, and Kiowa Kirin, outside the submitted work. A.T. reports consulting fees from Sanofi; payment or honoraria from Roche, Pfizer, BMS, GSK, AZ, and MSD; and support for attending meetings from GSK, and AZ. E.A. reports receiving consulting fees as a consultant or advisory role in MSD, Bristol-Myers, Roche, Boehringer Ingelheim, Pfizer, Novartis, AstraZeneca, Lilly, and Takeda; speaking fees from MSD, Bristol-Myers, Roche, Boehringer Ingelheim, Pfizer, Novartis, AstraZeneca, Lilly, and Takeda; he is also a co-founder of Trialing Health S.L. The other authors have no conflicts of interest to declare.